Process for the preparation of polymers having an inorganic backbone
    2.
    发明授权
    Process for the preparation of polymers having an inorganic backbone 失效
    制备具有无机主链的聚合物的方法

    公开(公告)号:US4942218A

    公开(公告)日:1990-07-17

    申请号:US197459

    申请日:1988-05-23

    IPC分类号: C08G79/14

    CPC分类号: C08G79/14

    摘要: The present invention provides a method of making a polymer by reacting, in the absence of water, an organic compound having the general formula R-H wherein R represents an organo radical having at least one unsaturated carbon-carbon bond and H is covalently bonded to one of said carbons, with PX.sub.3, wherein X is a halide radical, and zirconium ions to yield a reaction product and oxidizing and hydrolyzing such reaction product to yield a polymer represented by the general formula Zr(O.sub.3 PR).sub.n wherein n varies from about 1 to about 2.5. R may comprise sulfonic acid groups or may comprise sulfonatable site for sulfonation during the oxidation step. In either case, the resulting product is useful as an acid catalyst.

    摘要翻译: 本发明提供一种制备聚合物的方法,该方法通过在没有水的情况下使具有通式RH的有机化合物反应,其中R表示具有至少一个不饱和碳 - 碳键的有机基团,并且H共价键合至 所述碳与PX3反应,其中X为卤化物基团,锆离子产生反应产物,氧化和水解该反应产物,得到由通式Zr(O3PR)n表示的聚合物,其中n为约1至约 2.5。 R可以包含磺酸基团,或者可以包括在氧化步骤期间磺化的可磺化位点。 在任一情况下,所得产物可用作酸催化剂。

    Simultaneous assay for determining drugs
    4.
    发明授权
    Simultaneous assay for determining drugs 有权
    用于确定药物的同时测定

    公开(公告)号:US07947465B2

    公开(公告)日:2011-05-24

    申请号:US12187661

    申请日:2008-08-07

    IPC分类号: G01N33/00

    摘要: Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies. In an alternative procedure, the added drugs are not coupled to the microparticles but are pre-labeled, while the antibodies are pre-coupled to the microparticles, and the assay proceeds without further incubation. In both alternatives, the microparticles are ultimately recovered from the assay medium and from any unbound species, and the recovered microparticles are analyzed by flow cytometry to obtain indications of the presence of the various drugs in the sample in an inverse manner by detection of the label, each drug differentiable from the others by the distinguishing features of the microparticles.

    摘要翻译: 在同时测定中分析体液中所选择的药物组的药物的存在,其中将流体样品与附加量的所有药物,面板每种药物特异的抗体和微粒 ,将微粒分为子集,面板中每种药物的一个子集,以及与其他子集可区分的每个子集。 孵育在其中发生竞争性结合的液体培养基中进行,样品中的药物与添加到测定培养基中的药物与抗体结合。 在一个程序中,将所添加的药物预先偶联到微粒,而不是抗体,然后孵育后,用对抗体具有亲和性的标记配体进一步孵育微粒。 在替代方法中,所添加的药物不与微粒偶联,而是预先标记,而抗体预偶联于微粒,并且测定在不进一步孵育的情况下进行。 在两种替代方案中,微粒最终从测定培养基和任何未结合物质中回收,并且通过流式细胞术分析回收的微粒,以通过检测标签以相反的方式获得样品中各种药物的存在的迹象 ,每种药物通过微粒的区别特征与其他药物不同。

    Acid catalyzed process
    7.
    发明授权
    Acid catalyzed process 失效
    酸催化过程

    公开(公告)号:US5008468A

    公开(公告)日:1991-04-16

    申请号:US384251

    申请日:1989-08-21

    摘要: This invention provides an improved process for the conversion of reactant into a reaction product, in the presence of a solid acid catalyst comprising sulfonic acid groups covalently bonded to a polymeric chain, wherein the improvement comprises increasing the rate of conversion, on an equivalent sulfonic acid basis, by providing, as said polymeric chain a compound represented by the general formula:M(O.sub.3 ZO.sub.x R).sub.nwherein M is a tetravalent metal ion; Z is a pentavalent atom, selected from the group consisting of elements of Group V of the Periodic Table of the Elements having an atomic weight greater than 30; x varies from 0 to 1; R is select d from the group consisting or organo radicals and mixtures of hydrogen radicals and organo radicals; and n varies from 1 to 2; provided that n is 1 when R is terminated with a tri- or tetraoxy pentavalent atom.

    摘要翻译: 本发明提供了在包含共价键合到聚合物链上的磺酸基团的固体酸催化剂存在下将反应物转化成反应产物的改进方法,其中改进包括增加转化速率等同于磺酸 通过提供作为所述聚合物链的由通式M(O 3 Z x R)n表示的化合物,其中M是四价金属离子; Z是选自原子量大于30的元素周期表第Ⅴ族的元素的五价原子; x从0变化到1; R是选自下组的组或有机基团和氢基团和有机基团的混合物; n从1变化到2; 条件是当R用三或四氧基五价原子封端时n为1。

    Simultaneous assay for determining drugs
    8.
    发明授权
    Simultaneous assay for determining drugs 有权
    用于确定药物的同时测定

    公开(公告)号:US08137987B2

    公开(公告)日:2012-03-20

    申请号:US13086229

    申请日:2011-04-13

    IPC分类号: G01N33/52 G01N33/543

    摘要: Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies. In an alternative procedure, the added drugs are not coupled to the microparticles but are pre-labeled, while the antibodies are pre-coupled to the microparticles, and the assay proceeds without further incubation. In both alternatives, the microparticles are ultimately recovered from the assay medium and from any unbound species, and the recovered microparticles are analyzed by flow cytometry to obtain indications of the presence of the various drugs in the sample in an inverse manner by detection of the label, each drug differentiable from the others by the distinguishing features of the microparticles.

    摘要翻译: 在同时测定中分析体液中所选择的药物组的药物的存在,其中将流体样品与附加量的所有药物,面板每种药物特异的抗体和微粒 ,将微粒分为子集,面板中每种药物的一个子集,以及与其他子集可区分的每个子集。 孵育在其中发生竞争性结合的液体培养基中进行,样品中的药物与添加到测定培养基中的药物与抗体结合。 在一个程序中,将所添加的药物预先偶联到微粒,而不是抗体,然后孵育后,用对抗体具有亲和性的标记配体进一步孵育微粒。 在替代方法中,所添加的药物不与微粒偶联,而是预先标记,而抗体预偶联于微粒,并且测定在不进一步孵育的情况下进行。 在两种替代方案中,微粒最终从测定培养基和任何未结合物质中回收,并且通过流式细胞术分析回收的微粒,以通过检测标签以相反的方式获得样品中各种药物的存在的迹象 ,每种药物通过微粒的区别特征与其他药物不同。

    Multi-faceted, rotatable promotional display for vehicles
    10.
    发明授权
    Multi-faceted, rotatable promotional display for vehicles 失效
    多方位,可旋转的促销展示车

    公开(公告)号:US07877913B1

    公开(公告)日:2011-02-01

    申请号:US11958250

    申请日:2007-12-17

    申请人: David L. King

    发明人: David L. King

    IPC分类号: G09F21/04

    摘要: A multi-faceted, rotatable promotional display device for being retained relative to a vehicle for enabling the perception of multiple promotional messages from a single vantage point. A display casing with multiple display surfaces is rotatably retained relative to a base structure. Promotional messages are displayed relative to the display surfaces, and a drive arrangement rotates the display casing relative. The display casing can have a square, triangular, or other cross section. The base structure can have a cup portion with a raised peripheral ridge, and a shell can envelope the display casing. The display surfaces can be electronic display screens or light transmissive panels. A light source can be disposed within the display casing. A drive motor can be powered by a battery, a photovoltaic array, or a wind turbine. A clutch or a force sensor can prevent the application of excessive rotational force.

    摘要翻译: 一种多面,可旋转的促销显示装置,用于相对于车辆保持,以使得能够从单个有利位置感知多个促销消息。 具有多个显示表面的显示壳体相对于基座结构可旋转地保持。 相对于显示表面显示促销消息,并且驱动装置相对于显示器壳体旋转。 显示器壳体可以具有正方形,三角形或其它横截面。 基部结构可以具有凸起的周缘的杯部,壳可以包围显示壳。 显示表面可以是电子显示屏或透光面板。 光源可以设置在显示器壳体内。 驱动电机可由电池,光伏阵列或风力涡轮机供电。 离合器或力传感器可以防止施加过大的旋转力。